Pneumococcal Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type, By Product (Prevnar 13, VAXNEUVANCE, PNEUMOSIL), By End-use (Public Sector, Private Sector), By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within Immediate
Pneumococcal Vaccine Market Growth & Trends
The global pneumococcal vaccine market size is anticipated to reach USD 12.19 billion by 2030, registering a CAGR of 6.21% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of target diseases. Pneumococcus is the main cause of invasive disease, pneumonia, and upper respiratory tract infection and can lead to severe sequelae such as deafness, paralysis, intellectual disability, and other serious complications. For instance, in September 2023, the World Health Organization (WHO) estimated that Streptococcus pneumoniae is responsible for over 300,000 deaths annually among children under the age of 5 worldwide. The majority of these fatalities occur in developing nations. Globally, S. pneumoniae is the primary cause of pneumonia-related deaths, surpassing all other causes combined. The highest number of deaths due to this bacterium is observed in countries located in Africa and Asia.
Increasing government awareness programs regarding pneumonia immunization fuels the market growth. For instance, in September 2023, a survey conducted in September and October 2022 found that there's a need to extend the recommendations for the new 20-valent pneumococcal conjugate vaccine (PCV20) to adults who previously received the 13-valent pneumococcal conjugate vaccine (PCV13). The survey showed that healthcare providers need to be more aware of and implement pneumococcal vaccination recommendations better. After considering these findings, the Advisory Committee on Immunization Practices (ACIP) agreed to update the recommendations in late October 2022.
Moreover, product launches by key players is contributing to market growth. For instance, In October 2022, Merck & Co., Inc. received the European Commission’s (EC) approval for its Vaxneuvance, a pneumococcal vaccine. The approval allows product marketing in 27 European Union (EU) member states and Iceland, Norway, & Lichtenstein. Moreover, in September 2021, Minhai Biotechnology Co. Ltd. received approval from the National Medical Products Administration, China, for its 13-valent vaccine.
Growing R&D for developing novel vaccines boosting the growth of the market. In March 2024, SK Bioscience's announced expansion of its L House vaccine manufacturing facility in South Korea indicates a proactive approach to enhancing vaccine production capacity. This expansion, driven by the joint development of the pneumococcal conjugate vaccine candidate GBP410 with Sanofi, follows positive Phase 2 clinical trial results. SK Bioscience plans to conduct a global Phase 3 clinical trial in 2027, demonstrating a commitment to collaboration and global vaccine development.
Pneumococcal Vaccine Market Report Highlights
Pneumococcal Vaccine Market Growth & Trends
The global pneumococcal vaccine market size is anticipated to reach USD 12.19 billion by 2030, registering a CAGR of 6.21% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of target diseases. Pneumococcus is the main cause of invasive disease, pneumonia, and upper respiratory tract infection and can lead to severe sequelae such as deafness, paralysis, intellectual disability, and other serious complications. For instance, in September 2023, the World Health Organization (WHO) estimated that Streptococcus pneumoniae is responsible for over 300,000 deaths annually among children under the age of 5 worldwide. The majority of these fatalities occur in developing nations. Globally, S. pneumoniae is the primary cause of pneumonia-related deaths, surpassing all other causes combined. The highest number of deaths due to this bacterium is observed in countries located in Africa and Asia.
Increasing government awareness programs regarding pneumonia immunization fuels the market growth. For instance, in September 2023, a survey conducted in September and October 2022 found that there's a need to extend the recommendations for the new 20-valent pneumococcal conjugate vaccine (PCV20) to adults who previously received the 13-valent pneumococcal conjugate vaccine (PCV13). The survey showed that healthcare providers need to be more aware of and implement pneumococcal vaccination recommendations better. After considering these findings, the Advisory Committee on Immunization Practices (ACIP) agreed to update the recommendations in late October 2022.
Moreover, product launches by key players is contributing to market growth. For instance, In October 2022, Merck & Co., Inc. received the European Commission’s (EC) approval for its Vaxneuvance, a pneumococcal vaccine. The approval allows product marketing in 27 European Union (EU) member states and Iceland, Norway, & Lichtenstein. Moreover, in September 2021, Minhai Biotechnology Co. Ltd. received approval from the National Medical Products Administration, China, for its 13-valent vaccine.
Growing R&D for developing novel vaccines boosting the growth of the market. In March 2024, SK Bioscience's announced expansion of its L House vaccine manufacturing facility in South Korea indicates a proactive approach to enhancing vaccine production capacity. This expansion, driven by the joint development of the pneumococcal conjugate vaccine candidate GBP410 with Sanofi, follows positive Phase 2 clinical trial results. SK Bioscience plans to conduct a global Phase 3 clinical trial in 2027, demonstrating a commitment to collaboration and global vaccine development.
Pneumococcal Vaccine Market Report Highlights
- Based on type, Pneumococcal Conjugate Vaccine (PCV) segment led the market and is anticipated to grow at the fastest growth over the forecast period. PCV helps protect against pneumococcal disease, a leading cause of death among children under 5 years old
- Based on product, Prevnar 13 dominated the market and is expected to grow significantly during the forecast period. The vaccines under the Prevnar brand include Prevnar 13 and Prevnar 20. These are pneumococcal conjugate vaccines (PCVs) designed to protect against pneumococcal disease
- Based on end-use, the public sector led the market and is anticipated to grow at the fastest CAGR over the forecast period. The dominance of the public sector in the end use of pneumococcal vaccines, including hospitals, clinics, and healthcare facilities, can be attributed to several factors. These factors include the high prevalence of diseases, government initiatives to increase vaccination coverage
- North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Vaccine Type
1.2.2. Product
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Vaccine Type and Product outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
CHAPTER 3. PNEUMOCOCCAL VACCINE MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of target disease
3.2.1.2. Rising awareness and favorable government initiatives
3.2.1.3. Growing R&D for developing novel vaccines
3.2.2. Market restraint analysis
3.2.2.1. Supply chain and vaccine shortage challenges
3.2.2.2. Vaccine hesitancy and public awareness
3.3. Pneumococcal Vaccine Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Volume Analysis (Instruments)
CHAPTER 4. PNEUMOCOCCAL VACCINE MARKET: VACCINE TYPE ESTIMATES & TREND ANALYSIS
4.1. Global Pneumococcal Vaccine Market: Vaccine Type Dashboard
4.2. Global Pneumococcal Vaccine Market: Vaccine Type Movement Analysis
4.3. Global Pneumococcal Vaccine Market by Vaccine Type, Revenue
4.4. Pneumococcal Conjugate Vaccine
4.4.1. Pneumococcal Conjugate Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Pneumococcal Polysaccharide Vaccine
4.5.1. Pneumococcal Polysaccharide Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. PNEUMOCOCCAL VACCINE MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
5.1. Global Pneumococcal Vaccine Market: Product Dashboard
5.2. Global Pneumococcal Vaccine Market: Product Movement Analysis
5.3. Global Pneumococcal Vaccine Market by Product, Revenue
5.4. Prevnar
5.4.1. Prevnar 13 market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Synflorix
5.5.1. Synflorix market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Pneumovax
5.6.1. Pneumovax 23 market estimates and forecasts 2018 to 2030 (USD Million)
5.7. VAXNEUVANCE
5.7.1. VAXNEUVANCE market estimates and forecasts 2018 to 2030 (USD Million)
5.8. PNEUMOSIL
5.8.1. PNEUMOSIL market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Other Products
5.9.1. Other Products market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. PNEUMOCOCCAL VACCINE MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Global Pneumococcal Vaccine Market: End Use Dashboard
6.2. Global Pneumococcal Vaccine Market: End Use Movement Analysis
6.3. Global Pneumococcal Vaccine Market by End Use, Revenue
6.4. Public Sector
6.4.1. Public Sector market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Private Sector
6.5.1. Private Sector market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. PNEUMOCOCCAL VACCINE MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY VACCINE TYPE, PRODUCT, AND END USE
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Target disease prevalence
7.3.1.3. Regulatory framework/ reimbursement structure
7.3.1.4. Competitive scenario
7.3.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Target disease prevalence
7.3.2.3. Regulatory framework/ reimbursement structure
7.3.2.4. Competitive scenario
7.3.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Target disease prevalence
7.4.1.3. Regulatory framework/ reimbursement structure
7.4.1.4. Competitive scenario
7.4.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Target disease prevalence
7.4.2.3. Regulatory framework/ reimbursement structure
7.4.2.4. Competitive scenario
7.4.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Target disease prevalence
7.4.3.3. Regulatory framework/ reimbursement structure
7.4.3.4. Competitive scenario
7.4.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Target disease prevalence
7.4.4.3. Regulatory framework/ reimbursement structure
7.4.4.4. Competitive scenario
7.4.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Target disease prevalence
7.4.5.3. Regulatory framework/ reimbursement structure
7.4.5.4. Competitive scenario
7.4.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Target disease prevalence
7.4.6.3. Regulatory framework/ reimbursement structure
7.4.6.4. Competitive scenario
7.4.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Target disease prevalence
7.4.7.3. Regulatory framework/ reimbursement structure
7.4.7.4. Competitive scenario
7.4.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Target disease prevalence
7.4.8.3. Regulatory framework/ reimbursement structure
7.4.8.4. Competitive scenario
7.4.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Target disease prevalence
7.5.1.3. Regulatory framework/ reimbursement structure
7.5.1.4. Competitive scenario
7.5.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Target disease prevalence
7.5.2.3. Regulatory framework/ reimbursement structure
7.5.2.4. Competitive scenario
7.5.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Target disease prevalence
7.5.3.3. Regulatory framework/ reimbursement structure
7.5.3.4. Competitive scenario
7.5.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Target disease prevalence
7.5.4.3. Regulatory framework/ reimbursement structure
7.5.4.4. Competitive scenario
7.5.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Target disease prevalence
7.5.5.3. Regulatory framework/ reimbursement structure
7.5.5.4. Competitive scenario
7.5.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Target disease prevalence
7.5.6.3. Regulatory framework/ reimbursement structure
7.5.6.4. Competitive scenario
7.5.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Target disease prevalence
7.6.1.3. Regulatory framework/ reimbursement structure
7.6.1.4. Competitive scenario
7.6.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Mexico
7.6.2.1. Key country dynamics
7.6.2.2. Target disease prevalence
7.6.2.3. Regulatory framework/ reimbursement structure
7.6.2.4. Competitive scenario
7.6.2.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Target disease prevalence
7.6.3.3. Regulatory framework/ reimbursement structure
7.6.3.4. Competitive scenario
7.6.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Target disease prevalence
7.7.1.3. Regulatory framework/ reimbursement structure
7.7.1.4. Competitive scenario
7.7.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Target disease prevalence
7.7.2.3. Regulatory framework/ reimbursement structure
7.7.2.4. Competitive scenario
7.7.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Target disease prevalence
7.7.3.3. Regulatory framework/ reimbursement structure
7.7.3.4. Competitive scenario
7.7.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Target disease prevalence
7.7.4.3. Regulatory framework/ reimbursement structure
7.7.4.4. Competitive scenario
7.7.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Serum Institute of India Pvt. Ltd.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. CSL
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Sanofi
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. GSK plc
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Merck & Co., Inc.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Pfizer Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Walvax Biotechnology Co., Ltd
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Beijing Minhai Biotechnology Co.,Ltd (Subsidiary of Shenzhen Kangtai Biological Products Co. Ltd.)
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Vaccine Type
1.2.2. Product
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Vaccine Type and Product outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
CHAPTER 3. PNEUMOCOCCAL VACCINE MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of target disease
3.2.1.2. Rising awareness and favorable government initiatives
3.2.1.3. Growing R&D for developing novel vaccines
3.2.2. Market restraint analysis
3.2.2.1. Supply chain and vaccine shortage challenges
3.2.2.2. Vaccine hesitancy and public awareness
3.3. Pneumococcal Vaccine Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Volume Analysis (Instruments)
CHAPTER 4. PNEUMOCOCCAL VACCINE MARKET: VACCINE TYPE ESTIMATES & TREND ANALYSIS
4.1. Global Pneumococcal Vaccine Market: Vaccine Type Dashboard
4.2. Global Pneumococcal Vaccine Market: Vaccine Type Movement Analysis
4.3. Global Pneumococcal Vaccine Market by Vaccine Type, Revenue
4.4. Pneumococcal Conjugate Vaccine
4.4.1. Pneumococcal Conjugate Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Pneumococcal Polysaccharide Vaccine
4.5.1. Pneumococcal Polysaccharide Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. PNEUMOCOCCAL VACCINE MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
5.1. Global Pneumococcal Vaccine Market: Product Dashboard
5.2. Global Pneumococcal Vaccine Market: Product Movement Analysis
5.3. Global Pneumococcal Vaccine Market by Product, Revenue
5.4. Prevnar
5.4.1. Prevnar 13 market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Synflorix
5.5.1. Synflorix market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Pneumovax
5.6.1. Pneumovax 23 market estimates and forecasts 2018 to 2030 (USD Million)
5.7. VAXNEUVANCE
5.7.1. VAXNEUVANCE market estimates and forecasts 2018 to 2030 (USD Million)
5.8. PNEUMOSIL
5.8.1. PNEUMOSIL market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Other Products
5.9.1. Other Products market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. PNEUMOCOCCAL VACCINE MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Global Pneumococcal Vaccine Market: End Use Dashboard
6.2. Global Pneumococcal Vaccine Market: End Use Movement Analysis
6.3. Global Pneumococcal Vaccine Market by End Use, Revenue
6.4. Public Sector
6.4.1. Public Sector market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Private Sector
6.5.1. Private Sector market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. PNEUMOCOCCAL VACCINE MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY VACCINE TYPE, PRODUCT, AND END USE
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Target disease prevalence
7.3.1.3. Regulatory framework/ reimbursement structure
7.3.1.4. Competitive scenario
7.3.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Target disease prevalence
7.3.2.3. Regulatory framework/ reimbursement structure
7.3.2.4. Competitive scenario
7.3.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Target disease prevalence
7.4.1.3. Regulatory framework/ reimbursement structure
7.4.1.4. Competitive scenario
7.4.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Target disease prevalence
7.4.2.3. Regulatory framework/ reimbursement structure
7.4.2.4. Competitive scenario
7.4.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Target disease prevalence
7.4.3.3. Regulatory framework/ reimbursement structure
7.4.3.4. Competitive scenario
7.4.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Target disease prevalence
7.4.4.3. Regulatory framework/ reimbursement structure
7.4.4.4. Competitive scenario
7.4.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Target disease prevalence
7.4.5.3. Regulatory framework/ reimbursement structure
7.4.5.4. Competitive scenario
7.4.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Target disease prevalence
7.4.6.3. Regulatory framework/ reimbursement structure
7.4.6.4. Competitive scenario
7.4.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Target disease prevalence
7.4.7.3. Regulatory framework/ reimbursement structure
7.4.7.4. Competitive scenario
7.4.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Target disease prevalence
7.4.8.3. Regulatory framework/ reimbursement structure
7.4.8.4. Competitive scenario
7.4.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Target disease prevalence
7.5.1.3. Regulatory framework/ reimbursement structure
7.5.1.4. Competitive scenario
7.5.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Target disease prevalence
7.5.2.3. Regulatory framework/ reimbursement structure
7.5.2.4. Competitive scenario
7.5.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Target disease prevalence
7.5.3.3. Regulatory framework/ reimbursement structure
7.5.3.4. Competitive scenario
7.5.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Target disease prevalence
7.5.4.3. Regulatory framework/ reimbursement structure
7.5.4.4. Competitive scenario
7.5.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Target disease prevalence
7.5.5.3. Regulatory framework/ reimbursement structure
7.5.5.4. Competitive scenario
7.5.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Target disease prevalence
7.5.6.3. Regulatory framework/ reimbursement structure
7.5.6.4. Competitive scenario
7.5.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Target disease prevalence
7.6.1.3. Regulatory framework/ reimbursement structure
7.6.1.4. Competitive scenario
7.6.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Mexico
7.6.2.1. Key country dynamics
7.6.2.2. Target disease prevalence
7.6.2.3. Regulatory framework/ reimbursement structure
7.6.2.4. Competitive scenario
7.6.2.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Target disease prevalence
7.6.3.3. Regulatory framework/ reimbursement structure
7.6.3.4. Competitive scenario
7.6.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Target disease prevalence
7.7.1.3. Regulatory framework/ reimbursement structure
7.7.1.4. Competitive scenario
7.7.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Target disease prevalence
7.7.2.3. Regulatory framework/ reimbursement structure
7.7.2.4. Competitive scenario
7.7.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Target disease prevalence
7.7.3.3. Regulatory framework/ reimbursement structure
7.7.3.4. Competitive scenario
7.7.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Target disease prevalence
7.7.4.3. Regulatory framework/ reimbursement structure
7.7.4.4. Competitive scenario
7.7.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Serum Institute of India Pvt. Ltd.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. CSL
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Sanofi
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. GSK plc
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Merck & Co., Inc.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Pfizer Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Walvax Biotechnology Co., Ltd
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Beijing Minhai Biotechnology Co.,Ltd (Subsidiary of Shenzhen Kangtai Biological Products Co. Ltd.)
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviation
Table 2 North America Pneumococcal Vaccine Market, 2018 - 2030 (USD Million)
Table 3 North America Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 4 North America Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 5 North America Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 6 U.S. Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 7 U.S. Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 8 U.S. Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 9 Canada Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 10 Canada Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 11 Canada Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 12 Europe Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)
Table 13 Europe Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 14 Europe Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 15 Europe Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 16 Germany Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 17 Germany Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 18 Germany Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 19 UK Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 20 UK Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 21 UK Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 22 France Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 23 France Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 24 France Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 25 Italy Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 26 Italy Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 27 Italy Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 28 Spain Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 29 Spain Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 30 Spain Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 31 Denmark Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 32 Denmark Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 33 Denmark Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 34 Sweden Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 35 Sweden Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 36 Sweden Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 37 Norway Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 38 Norway Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 39 Norway Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 40 Asia Pacific Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 43 Aisa Pacific Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 44 China Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 45 China Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 46 China Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 47 Japan Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 48 Japan Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 49 Japan Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 50 India Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 51 India Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 52 India Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 53 South Korea Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 54 South Korea Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 55 South Korea Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 56 Australia Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 57 Australia Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 58 Australia Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 59 Thailand Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 60 Thailand Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 61 Thailand Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 62 Latin America Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)
Table 63 Latin America Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 64 Latin America Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 65 Latin America Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 66 Brazil Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 67 Brazil Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 68 Brazil Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 69 Mexico Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 70 Mexico Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 71 Mexico Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 72 Argentina Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 73 Argentina Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 74 Argentina Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 75 MEA Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)
Table 76 MEA Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 77 MEA Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 78 MEA Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 79 South Africa Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 80 South Africa Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 81 South Africa Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 85 UAE Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 86 UAE Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 87 UAE Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 88 Kuwait Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 89 Kuwait Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 90 Kuwait Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 1 List of abbreviation
Table 2 North America Pneumococcal Vaccine Market, 2018 - 2030 (USD Million)
Table 3 North America Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 4 North America Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 5 North America Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 6 U.S. Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 7 U.S. Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 8 U.S. Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 9 Canada Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 10 Canada Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 11 Canada Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 12 Europe Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)
Table 13 Europe Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 14 Europe Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 15 Europe Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 16 Germany Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 17 Germany Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 18 Germany Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 19 UK Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 20 UK Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 21 UK Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 22 France Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 23 France Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 24 France Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 25 Italy Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 26 Italy Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 27 Italy Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 28 Spain Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 29 Spain Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 30 Spain Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 31 Denmark Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 32 Denmark Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 33 Denmark Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 34 Sweden Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 35 Sweden Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 36 Sweden Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 37 Norway Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 38 Norway Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 39 Norway Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 40 Asia Pacific Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 43 Aisa Pacific Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 44 China Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 45 China Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 46 China Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 47 Japan Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 48 Japan Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 49 Japan Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 50 India Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 51 India Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 52 India Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 53 South Korea Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 54 South Korea Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 55 South Korea Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 56 Australia Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 57 Australia Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 58 Australia Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 59 Thailand Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 60 Thailand Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 61 Thailand Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 62 Latin America Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)
Table 63 Latin America Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 64 Latin America Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 65 Latin America Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 66 Brazil Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 67 Brazil Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 68 Brazil Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 69 Mexico Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 70 Mexico Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 71 Mexico Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 72 Argentina Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 73 Argentina Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 74 Argentina Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 75 MEA Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)
Table 76 MEA Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 77 MEA Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 78 MEA Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 79 South Africa Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 80 South Africa Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 81 South Africa Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 85 UAE Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 86 UAE Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 87 UAE Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
Table 88 Kuwait Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
Table 89 Kuwait Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
Table 90 Kuwait Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Pneumococcal vaccines market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Vaccine type and product segment snapshot
Fig. 10 End-use segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Parent market (USD billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Pneumococcal vaccine market: Vaccine type outlook and key takeaways
Fig. 17 Pneumococcal vaccine market: Vaccine type movement analysis
Fig. 18 Pneumococcal Conjugate Vaccine (PCV) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Pneumococcal Polysaccharide Vaccine (PPV) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Pneumococcal vaccine market: Product outlook and key takeaways
Fig. 21 Pneumococcal vaccine market: Product movement analysis
Fig. 22 Prevnar market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Synflorix market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Pneumovax 23 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 VAXNEUVANCE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 PNEUMOSIL market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Other products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Pneumococcal vaccine market: End-use outlook and key takeaways
Fig. 29 Pneumococcal vaccine market: End-use movement analysis
Fig. 30 Public sector market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Private sector market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Pneumococcal vaccine market revenue, by region, 2023 & 2030 (USD Million)
Fig. 33 Regional marketplace: Key takeaways
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 North America pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Key country dynamics
Fig. 37 U.S. pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Key country dynamics
Fig. 40 Canada pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Vaccine testing and approval process in Canada
Fig. 42 Europe pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Key country dynamics
Fig. 44 UK pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Key country dynamics
Fig. 46 Germany pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Key country dynamics
Fig. 48 France pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Key country dynamics
Fig. 50 Spain pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 Italy pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Key country dynamics
Fig. 54 Denmark pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Sweden pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Norway pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Rest of Europe pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Asia Pacific pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Japan pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 China Pneumococcal Vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 China regulatory details
Fig. 66 Key country dynamics
Fig. 67 India pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Australia pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Thailand pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Key country dynamics
Fig. 73 South Korea pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 South Korea reimbursement scenario
Fig. 75 Rest of Asia Pacific pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Latin America pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Brazil pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Brazil regulation details
Fig. 80 Brazil reimbursement scenario
Fig. 81 Key country dynamics
Fig. 82 Mexico pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Argentina pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Argentina regulatory framework
Fig. 87 Rest of Latin America pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 MEA pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Key country dynamics
Fig. 90 South Africa pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Key country dynamics
Fig. 92 Saudi Arabia pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Key country dynamics
Fig. 94 UAE pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 Kuwait pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Rest of MEA pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Pneumococcal vaccines market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Vaccine type and product segment snapshot
Fig. 10 End-use segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Parent market (USD billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Pneumococcal vaccine market: Vaccine type outlook and key takeaways
Fig. 17 Pneumococcal vaccine market: Vaccine type movement analysis
Fig. 18 Pneumococcal Conjugate Vaccine (PCV) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Pneumococcal Polysaccharide Vaccine (PPV) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Pneumococcal vaccine market: Product outlook and key takeaways
Fig. 21 Pneumococcal vaccine market: Product movement analysis
Fig. 22 Prevnar market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Synflorix market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Pneumovax 23 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 VAXNEUVANCE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 PNEUMOSIL market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Other products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Pneumococcal vaccine market: End-use outlook and key takeaways
Fig. 29 Pneumococcal vaccine market: End-use movement analysis
Fig. 30 Public sector market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Private sector market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Pneumococcal vaccine market revenue, by region, 2023 & 2030 (USD Million)
Fig. 33 Regional marketplace: Key takeaways
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 North America pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Key country dynamics
Fig. 37 U.S. pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Key country dynamics
Fig. 40 Canada pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Vaccine testing and approval process in Canada
Fig. 42 Europe pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Key country dynamics
Fig. 44 UK pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Key country dynamics
Fig. 46 Germany pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Key country dynamics
Fig. 48 France pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Key country dynamics
Fig. 50 Spain pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 Italy pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Key country dynamics
Fig. 54 Denmark pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Sweden pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Norway pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Rest of Europe pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Asia Pacific pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Japan pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 China Pneumococcal Vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 China regulatory details
Fig. 66 Key country dynamics
Fig. 67 India pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Australia pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Thailand pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Key country dynamics
Fig. 73 South Korea pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 South Korea reimbursement scenario
Fig. 75 Rest of Asia Pacific pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Latin America pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Brazil pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Brazil regulation details
Fig. 80 Brazil reimbursement scenario
Fig. 81 Key country dynamics
Fig. 82 Mexico pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Argentina pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Argentina regulatory framework
Fig. 87 Rest of Latin America pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 MEA pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Key country dynamics
Fig. 90 South Africa pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Key country dynamics
Fig. 92 Saudi Arabia pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Key country dynamics
Fig. 94 UAE pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 Kuwait pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Rest of MEA pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
